|
**Overview**: Pemphigus Antibody IFA Panel**Introduction**: The Pemphigus Antibody IFA Panel is a diagnostic tool designed to screen for pemphigus using serum samples. In India, pemphigus vulgaris is the most common autoimmune blistering disease (prevalence ~1-2 per 100,000, higher in northern states), causing painful oral/skin blisters with high morbidity from infection and steroid side effects. Anti-desmoglein 1 and 3 antibodies are highly specific. High burden from underdiagnosis in rural/low-SES patients, limited immunofluorescence labs, delayed rituximab/steroid therapy leading to sepsis or mortality. Per dermatology practices aligned with ICMR and Indian Association of Dermatologists guidelines, the test employs immunoassay for anti-Dsg1/Dsg3 over 1-2 days with high specificity, valuable for confirming pemphigus and monitoring disease activity. This diagnostic falls under autoimmune skin screening and targets patients with blisters, erosions, or oral ulcers, addressing accurate detection to guide immunosuppression. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its serum-based approach ensures reliable antibody detection.**Other Names**: Pemphigus IFA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Dsg ELISA standard; in India, used in blistering disease clinics.**Purpose**: The test screens for 2 parameters including anti-desmoglein 1 to guide pemphigus diagnosis, detect specific antibodies, inform therapy.**Test Parameters**: 1. Anti-Desmoglein 1, 2. Anti-Desmoglein 3.**Pretest Condition**: No fasting required; patients should report blisters, oral erosions.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on blister onset, sites, mucosal involvement, prior steroids.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated pemphigus including infection, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive anti-Dsg indicates pemphigus, necessitating specialist input. Negative may require follow-up if clinical suspicion high.**Specialist Consultation**: Dermatologists should be consulted for management.**Additional Supporting Tests**: Skin biopsy with DIF for confirmation.**Test Limitations**: May be negative in early/mild disease; comprehensive approach required.**References**: Indian Journal of Dermatology 2024, Pemphigus Studies India 2023. |
